• Tocilizumab to mitigate cytokine storm • Prospective observational study
• Severe or critical COVID-19 infection
• 25 to 88 years of age
•  N = 21 tocilizumab + standard therapy
• 42.9% had CVD • 4–8 mg/kg or 400 mg tocilizumab i.v. once
• 85.7% received single dose of tocilizumab, 14.3% required second dose within 12 h of first dose • Fever normalized within 24 h
• Reduced O2 therapy requirements
• Minimal improvement in IL-6 levels
• CT lung lesion improvement
• All patients discharged • Limited sample size and no control group
• Tocilizumab treatment in severe COVID-19 cases may improve clinical symptoms in hyperinflammatory state (Xu et al., 2020)